戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 al hypoglycaemic events have lower levels of betatrophin.
2                                              Betatrophin, a 198-amino acid protein secreted by liver
3                      The recent discovery of betatrophin, a protein secreted by the liver and white a
4 ta show strong positive associations between betatrophin and FBG and insulin resistance in non-diabet
5                                              Betatrophin/ANGPTL8 is a newly identified hormone produc
6      These results put into question whether betatrophin can be developed as a therapeutic approach f
7                                Expression of betatrophin correlates with beta cell proliferation in o
8  receptor antagonist S961, shown to increase betatrophin gene expression and stimulate beta-cell repl
9 owed that subjects in the highest tertile of betatrophin had higher odds of having T2D (odd ratio [OR
10                                              Betatrophin has not yet been shown to have an effect on
11                                              Betatrophin has previously been named RIFL, lipasin, and
12             None of these factors, including betatrophin, have displayed the same activity in clinica
13                      Transient expression of betatrophin in mouse liver significantly and specificall
14      So far, no data exist about the role of betatrophin in pregnant women with a history of Roux-En-
15  TC and LDL showed negative association with betatrophin in T2D subjects.
16                                              Betatrophin is a liver and adipose tissue-derived protei
17                                              Betatrophin is a newly described hormone, which potently
18                           Therefore, lipasin/betatrophin is nutritionally-regulated hepatokine that i
19 ny endocrine and paracrine factors, of which betatrophin is the newest described, increase beta cell
20 n (also known as C19ORF80, RIFL, ANGPTL8 and betatrophin) is a newly discovered circulating factor th
21 lternatively called TD26, RIFL, Lipasin, and Betatrophin) is a newly recognized ANGPTL family member
22                        Little is known about betatrophin level in humans and its association with T2D
23           During the OGTT, basal and dynamic betatrophin levels at 60' were positively associated wit
24    Our data show a significant difference in betatrophin levels between non-diabetic (731.3 (59.5-106
25 there was a decrease in basal and stimulated betatrophin levels during the OGTT in all three patient
26 dial hypoglycaemic events, basal and dynamic betatrophin levels during the OGTT were lower than in th
27                                        Serum betatrophin levels in humans correlate with improved adi
28             To examine subfatin, preptin and betatrophin levels in plasma and aqueous in patients wit
29     Plasma and aqueous subfatin, preptin and betatrophin levels were analyzed by ELISA (enzyme-linked
30                           Plasma and aqueous betatrophin levels were higher in Group DR compared to g
31  also taken for plasma subfatin, preptin and betatrophin levels.
32                        Subfatin, preptin and betatrophin molecules may have an important role in the
33          At present, however, the effects of betatrophin on human beta-cells are not known.
34 ike protein 8 (ANGPTL8) was the long-sought "betatrophin" that could control pancreatic beta cell pro
35     Using this model, we identify a hormone, betatrophin, that is primarily expressed in liver and fa
36                                        Thus, betatrophin treatment could augment or replace insulin i
37                              Plasma level of betatrophin was measured by ELISA in 1603 subjects: 1047
38           It was only in the RYGB group that betatrophin was negatively related to the disposition in
39                                              Betatrophin was positively correlated with age, BMI, wai